human recombinant c5a Search Results


94
Hycult Biotech recombinant human c5a
FIGURE 2. <t>C5a</t> contributes to the early PMN activation during whole-blood infection with C. albicans. Human whole blood was treated with an anti- C5a Ab (IFX-1) prior to inoculation of C. albicans for 10 and 60 min to investigate the impact of C5a on activation of blood PMN. Samples were compared with either nontreated or IgG4-containig C. albicans–infected blood. (A) The percentages of ROI formation in samples inoculated with C. albicans were calculated relative to basal levels in the mock-infected sample (set to 100%). The bars show mean 6 SD of at least seven independent experiments with blood from different donors; **p , 0.01. (B) Differential regulation of surface exposure of degranulation marker CD66b is shown in histograms. Gray filled histograms indicate basal expression on PMN in the mock-infected sample. Black open histograms indicate surface levels following C. albicans infection and differentiate between PMN without fungal contact (dashed line) and PMN that interact with C. albicans (dotted line). C. albicans samples were either nontreated (a) or preincubated with IgG4 (b) or anti-C5a (c). (C) Plasma samples of whole-blood infection experiments were analyzed for secretion of antimicrobial peptides from primary (MPO, elastase-2) and secondary neutrophilic granules (NGAL, lactoferrin) and the release of IL-8. In comparison with non- (white bars) and IgG4-treated infected samples (striped bars), presence of anti-C5a Ab (black bars) significantly prevented the increase in plasma levels of lactoferrin, NGAL and IL-8 in response to C. albicans (t = 60 min). Gray bars indicate basal plasma levels within mock-infected blood. Bars show means 6 SD of nine independent experiments with whole blood from different donors. **p , 0.01. ns, nonsignificant.
Recombinant Human C5a, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/C5a%2C+Human%2C+Recombinant/pm25539819-73-3-6
Average 94 stars, based on 1 article reviews
recombinant human c5a - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
R&D Systems c5a
( A ) Shown are representative fields from 3 independent experiments. Complement proteins C3a and <t>C5a</t> increased the expression of ECM proteins in THP1 macrophages, BMDMs, and HK2 proximal tubule cells after 72 hours of treatment in serum-free medium. Scale bars: 50 μm. ( B – D ) The scatter plots show the mean staining intensity per THP-1 macrophage ( B ), BMDM ( C ), and HK2 proximal tubule cell ( D ), normalized to expression levels in their respective vehicle-treated groups. Each data point corresponds to quantified fluorescence intensity in a single field of view (FOV) from the microscope, and the larger dots represent the average of FOVs in biological replicates, each of which is color coded. RT-qPCR analysis of ECM protein coding genes were measured in BMDMs ( E ) and in HK2 proximal tubule cells ( F ). Gene expression was normalized to the expression of 18S ribosomal RNA in the same sample and then normalized to the expression level of vehicle-treated group ( n = 4). * P < 0.05, ** P < 0.01, and *** P < 0.001 by 2-tailed Student’s t test.
C5a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/Recombinant+Human+Complement+Component+C5a+Protein/pmc12483563-170-38-39
Average 93 stars, based on 1 article reviews
c5a - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
R&D Systems human recombinant c5a protein
Time- and dose-dependent cytotoxicity and apoptosis assays on Glomerular Endothelial Cells (GECs) and Podocytes. GECs. Time-dependent XTT citotoxity assay on GECs ( A ) and podocytes ( B ) incubated with a medium containing CK (20 ng/mL TNF-α, 2.5 ng/mL IL-6, and 50 ng/mL human <t>recombinant</t> <t>C5a</t> protein) or vehicle alone at different time-points (12, 18, 24, 36, 48 h) Significant differences in viability were observed on both GECs and podocytes at 18, 24, 36, and 48 h (* p < 0.05, CK vs. vehicle). At 12 h, only the GECs (A) had different viability between treated (CK) and control cells (vehicle, * p < 0.05, CK vs. vehicle). Cytotoxicity tests by XTT ( C ) and apoptosis by TUNEL assay ( D ), evaluating the protective dose of EPC-derived EVs on GECs (black columns) and podocytes (white columns) after 24 h. Incubation with CK alone was effective in inducing cytotoxic (C) and apoptotic damage (D) in both cell types (* p < 0.05, CK vs. vehicle). Adding 1 or 10 μg/mL EPC-derived EVs to cells incubated with CK did not significantly reduce cell damage (* p < 0.05, CK + 1 μg/mL EV and CK + 10 μg/mL EV vs. vehicle), except with GEC incubated with 10 μg/mL EV in TUNEL assay (§ CK + 10 μg/mL EV vs. CK). In contrast, the adding of 25 or 50 μg/mL EPC-derived EVs to cells incubated with CK significantly reduced cell damage at the level of GECs and podocytes (§ p < 0.05, CK + 25 μg/mL EV and CK + 50 μg/mL EV vs. CK). XTT assays are reported as average optical density (O.D.) intensity ± 1SD. For TUNEL assays, data are expressed as the average number of green fluorescent apoptotic cells ± 1 SD. We performed three experiments for each test and the statistical analysis by ANOVA with Newmann–Keuls multiple comparison test.
Human Recombinant C5a Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/Recombinant+Human+Complement+Component+C5a+Protein%2C+CF/pmc08304261-60-25-29
Average 93 stars, based on 1 article reviews
human recombinant c5a protein - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
R&D Systems recombinant human complement component c5a protein
Time- and dose-dependent cytotoxicity and apoptosis assays on Glomerular Endothelial Cells (GECs) and Podocytes. GECs. Time-dependent XTT citotoxity assay on GECs ( A ) and podocytes ( B ) incubated with a medium containing CK (20 ng/mL TNF-α, 2.5 ng/mL IL-6, and 50 ng/mL human <t>recombinant</t> <t>C5a</t> protein) or vehicle alone at different time-points (12, 18, 24, 36, 48 h) Significant differences in viability were observed on both GECs and podocytes at 18, 24, 36, and 48 h (* p < 0.05, CK vs. vehicle). At 12 h, only the GECs (A) had different viability between treated (CK) and control cells (vehicle, * p < 0.05, CK vs. vehicle). Cytotoxicity tests by XTT ( C ) and apoptosis by TUNEL assay ( D ), evaluating the protective dose of EPC-derived EVs on GECs (black columns) and podocytes (white columns) after 24 h. Incubation with CK alone was effective in inducing cytotoxic (C) and apoptotic damage (D) in both cell types (* p < 0.05, CK vs. vehicle). Adding 1 or 10 μg/mL EPC-derived EVs to cells incubated with CK did not significantly reduce cell damage (* p < 0.05, CK + 1 μg/mL EV and CK + 10 μg/mL EV vs. vehicle), except with GEC incubated with 10 μg/mL EV in TUNEL assay (§ CK + 10 μg/mL EV vs. CK). In contrast, the adding of 25 or 50 μg/mL EPC-derived EVs to cells incubated with CK significantly reduced cell damage at the level of GECs and podocytes (§ p < 0.05, CK + 25 μg/mL EV and CK + 50 μg/mL EV vs. CK). XTT assays are reported as average optical density (O.D.) intensity ± 1SD. For TUNEL assays, data are expressed as the average number of green fluorescent apoptotic cells ± 1 SD. We performed three experiments for each test and the statistical analysis by ANOVA with Newmann–Keuls multiple comparison test.
Recombinant Human Complement Component C5a Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/Recombinant+Human+Complement+Component+C5a+Protein/pmc06608085-138-19-27
Average 94 stars, based on 1 article reviews
recombinant human complement component c5a protein - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Cusabio recombinant human c5a anaphylotoxin chemotactic receptor 2 c5ar2
Selected potential paclitaxel targets and their predicted affinity.
Recombinant Human C5a Anaphylotoxin Chemotactic Receptor 2 C5ar2, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/Recombinant+Human+C5a+anaphylatoxin+chemotactic+receptor+2/pmc09130998-189-7-15
Average 93 stars, based on 1 article reviews
recombinant human c5a anaphylotoxin chemotactic receptor 2 c5ar2 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
R&D Systems human complement component c5a
(a,b) Degradation of recombinant <t>C5a</t> by cultures supernatant containing the C5a-peptidase enzyme (ScpA). GAS was grown in CDM without or with Asn or/and LL-37. Supernatants of the indicated strains were incubated with recombinant human C5a, resolved on Tris-tricine gels, and visualized by Coomassie blue staining. M represents a marker, and an empty arrow is the cleaved C5a. The data are representative of 2 independent experiments. (c,d) Quantitation of IL-8 degradation by ScpC present in the supernatants of the indicated strains by ELISA. n=2 . The data shown represent the means ± S.D. (e) Asn does not affect in-vitro CovR phosphorylation . Purified CovR was incubated in the absence (−) and presence (+) of acetyl phosphate (Ac-P) as a phosphate donor and the indicated concentrations of Asn (µg ml -1 ). The protein samples were resolved on Phos-tag SDS-PAGE gel and visualized.
Human Complement Component C5a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/Recombinant+Human+Complement+Component+C5a+Protein%2C+CF/bio_rxiv__2024__07__08__602371-285-11-15
Average 93 stars, based on 1 article reviews
human complement component c5a - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
Hycult Biotech c5a desarg
(a,b) Degradation of recombinant <t>C5a</t> by cultures supernatant containing the C5a-peptidase enzyme (ScpA). GAS was grown in CDM without or with Asn or/and LL-37. Supernatants of the indicated strains were incubated with recombinant human C5a, resolved on Tris-tricine gels, and visualized by Coomassie blue staining. M represents a marker, and an empty arrow is the cleaved C5a. The data are representative of 2 independent experiments. (c,d) Quantitation of IL-8 degradation by ScpC present in the supernatants of the indicated strains by ELISA. n=2 . The data shown represent the means ± S.D. (e) Asn does not affect in-vitro CovR phosphorylation . Purified CovR was incubated in the absence (−) and presence (+) of acetyl phosphate (Ac-P) as a phosphate donor and the indicated concentrations of Asn (µg ml -1 ). The protein samples were resolved on Phos-tag SDS-PAGE gel and visualized.
C5a Desarg, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/C5a+des+Arg%2C+Human%2C+Recombinant/pmc05790441-156-7-11
Average 90 stars, based on 1 article reviews
c5a desarg - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Complement Technology Inc recombinant human c3a c5a
RNA interference suppresses local complement activation. BALF collected from Figure 1 were analyzed for C3a (A) and <t>C5a</t> (B) levels in the lung by ELISA. Values: Means ± SEM. (n=5-7 per group). One-way ANOVA, Newman-Keuls (A, B). Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. Results are representative of three independent experiments.
Recombinant Human C3a C5a, supplied by Complement Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/recombinant+human+c3a+c5a/pmc05786162-113-7-10
Average 90 stars, based on 1 article reviews
recombinant human c3a c5a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Complement Technology Inc native (not recombinant) human c5a
RNA interference suppresses local complement activation. BALF collected from Figure 1 were analyzed for C3a (A) and <t>C5a</t> (B) levels in the lung by ELISA. Values: Means ± SEM. (n=5-7 per group). One-way ANOVA, Newman-Keuls (A, B). Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. Results are representative of three independent experiments.
Native (Not Recombinant) Human C5a, supplied by Complement Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/native++not+recombinant++human+c5a/pmc07053518-401-2-7
Average 90 stars, based on 1 article reviews
native (not recombinant) human c5a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Ciba Geigy recombinant human c5a
PMN migrate using CD18-independent mechanisms across T84 monolayers growing on the bottom of Transwell filters. Migration to fMLP (10−7m), <t>C5a</t> (10−8m), IL-8 (10−8m) and LTB4 (10−6m) of PMN without added mAb (▪) or anti-CD18 mAb pretreated PMN (). The data is from between six and 11 experiments and the mean of means ± standard error of the mean are shown. Values with control mAb treatment were similar to migration in absence of antibody for each chemoattractant (not shown).
Recombinant Human C5a, supplied by Ciba Geigy, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/recombinant+human+c5a/pmc01809036-98-0-7
Average 90 stars, based on 1 article reviews
recombinant human c5a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Fluka Chemical human recombinant c5a
NF-κB activation 1 hour after in vitro or in vivo stimulation with IgG immune complexes in the absence or presence of <t>C5a</t> or MAC, as detected by the electrophoretic mobility shift assay (EMSA). Nuclear extracts of alveolar macrophages or whole lung nuclei were used. The position of NF-κB (p50, p65) is indicated by the arrows.
Human Recombinant C5a, supplied by Fluka Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+recombinant+c5a/human+recombinant+c5a/pmc01866590-32-0-6
Average 90 stars, based on 1 article reviews
human recombinant c5a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


FIGURE 2. C5a contributes to the early PMN activation during whole-blood infection with C. albicans. Human whole blood was treated with an anti- C5a Ab (IFX-1) prior to inoculation of C. albicans for 10 and 60 min to investigate the impact of C5a on activation of blood PMN. Samples were compared with either nontreated or IgG4-containig C. albicans–infected blood. (A) The percentages of ROI formation in samples inoculated with C. albicans were calculated relative to basal levels in the mock-infected sample (set to 100%). The bars show mean 6 SD of at least seven independent experiments with blood from different donors; **p , 0.01. (B) Differential regulation of surface exposure of degranulation marker CD66b is shown in histograms. Gray filled histograms indicate basal expression on PMN in the mock-infected sample. Black open histograms indicate surface levels following C. albicans infection and differentiate between PMN without fungal contact (dashed line) and PMN that interact with C. albicans (dotted line). C. albicans samples were either nontreated (a) or preincubated with IgG4 (b) or anti-C5a (c). (C) Plasma samples of whole-blood infection experiments were analyzed for secretion of antimicrobial peptides from primary (MPO, elastase-2) and secondary neutrophilic granules (NGAL, lactoferrin) and the release of IL-8. In comparison with non- (white bars) and IgG4-treated infected samples (striped bars), presence of anti-C5a Ab (black bars) significantly prevented the increase in plasma levels of lactoferrin, NGAL and IL-8 in response to C. albicans (t = 60 min). Gray bars indicate basal plasma levels within mock-infected blood. Bars show means 6 SD of nine independent experiments with whole blood from different donors. **p , 0.01. ns, nonsignificant.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a.

doi: 10.4049/jimmunol.1401845

Figure Lengend Snippet: FIGURE 2. C5a contributes to the early PMN activation during whole-blood infection with C. albicans. Human whole blood was treated with an anti- C5a Ab (IFX-1) prior to inoculation of C. albicans for 10 and 60 min to investigate the impact of C5a on activation of blood PMN. Samples were compared with either nontreated or IgG4-containig C. albicans–infected blood. (A) The percentages of ROI formation in samples inoculated with C. albicans were calculated relative to basal levels in the mock-infected sample (set to 100%). The bars show mean 6 SD of at least seven independent experiments with blood from different donors; **p , 0.01. (B) Differential regulation of surface exposure of degranulation marker CD66b is shown in histograms. Gray filled histograms indicate basal expression on PMN in the mock-infected sample. Black open histograms indicate surface levels following C. albicans infection and differentiate between PMN without fungal contact (dashed line) and PMN that interact with C. albicans (dotted line). C. albicans samples were either nontreated (a) or preincubated with IgG4 (b) or anti-C5a (c). (C) Plasma samples of whole-blood infection experiments were analyzed for secretion of antimicrobial peptides from primary (MPO, elastase-2) and secondary neutrophilic granules (NGAL, lactoferrin) and the release of IL-8. In comparison with non- (white bars) and IgG4-treated infected samples (striped bars), presence of anti-C5a Ab (black bars) significantly prevented the increase in plasma levels of lactoferrin, NGAL and IL-8 in response to C. albicans (t = 60 min). Gray bars indicate basal plasma levels within mock-infected blood. Bars show means 6 SD of nine independent experiments with whole blood from different donors. **p , 0.01. ns, nonsignificant.

Article Snippet: In selected experiments, recombinant human C5a (Hycult Biotech) was added at different concentrations (as indicated) and PMN activation was analyzed by flow cytometry following 30 min of incubation.

Techniques: Activation Assay, Infection, Marker, Expressing, Clinical Proteomics, Comparison

FIGURE 3. Both C5a and C. albicans phagocytosis trigger decrease in C5aR surface expression on PMN. Comparison of C5aR expression on primary and blood PMN after 10 min [(a), top and bottom, respectively] and 60 min [(b), top and bottom, respectively] confrontation with C. albicans. Gray filled histograms show basal expression in mock-infected samples. Black open histograms indicate surface levels following C. albicans infection and differentiate between PMN without fungal contact (dashed line) and PMN that interact with C. albicans (dotted line). Data from one of at least three independent experiments with virtually identical results are shown.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a.

doi: 10.4049/jimmunol.1401845

Figure Lengend Snippet: FIGURE 3. Both C5a and C. albicans phagocytosis trigger decrease in C5aR surface expression on PMN. Comparison of C5aR expression on primary and blood PMN after 10 min [(a), top and bottom, respectively] and 60 min [(b), top and bottom, respectively] confrontation with C. albicans. Gray filled histograms show basal expression in mock-infected samples. Black open histograms indicate surface levels following C. albicans infection and differentiate between PMN without fungal contact (dashed line) and PMN that interact with C. albicans (dotted line). Data from one of at least three independent experiments with virtually identical results are shown.

Article Snippet: In selected experiments, recombinant human C5a (Hycult Biotech) was added at different concentrations (as indicated) and PMN activation was analyzed by flow cytometry following 30 min of incubation.

Techniques: Expressing, Comparison, Infection

FIGURE 4. Effects of C5a on C. albicans–induced PMN activation in whole blood are mediated by C5aR. Presence of an anti-C5aR Ab during whole- blood infection with C. albicans showed that C5a acts via C5aR to modulate early PMN activation. (A) ROI formation in C. albicans samples (non-, IgG2a-, or anti–C5aR-treated) were normalized against basal levels in mock-infected blood (set to 100%). The bars show mean 6 SD of five independent experiments with blood from different donors. *p , 0.05. (B) Surface expression of CD66b is shown in histograms. Gray filled histograms indicate basal expression on PMN within mock-infected sample. Black open histograms indicate surface levels following C. albicans infection and differentiate between PMN without fungal contact (dashed line) and PMN that interact with C. albicans (dotted line). C. albicans–infected samples were either nontreated (a) or preincubated with IgG2a (b) or anti-C5aR (c). Data from one of at least three independent experiments with virtually identical results are shown. ns, nonsignificant.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a.

doi: 10.4049/jimmunol.1401845

Figure Lengend Snippet: FIGURE 4. Effects of C5a on C. albicans–induced PMN activation in whole blood are mediated by C5aR. Presence of an anti-C5aR Ab during whole- blood infection with C. albicans showed that C5a acts via C5aR to modulate early PMN activation. (A) ROI formation in C. albicans samples (non-, IgG2a-, or anti–C5aR-treated) were normalized against basal levels in mock-infected blood (set to 100%). The bars show mean 6 SD of five independent experiments with blood from different donors. *p , 0.05. (B) Surface expression of CD66b is shown in histograms. Gray filled histograms indicate basal expression on PMN within mock-infected sample. Black open histograms indicate surface levels following C. albicans infection and differentiate between PMN without fungal contact (dashed line) and PMN that interact with C. albicans (dotted line). C. albicans–infected samples were either nontreated (a) or preincubated with IgG2a (b) or anti-C5aR (c). Data from one of at least three independent experiments with virtually identical results are shown. ns, nonsignificant.

Article Snippet: In selected experiments, recombinant human C5a (Hycult Biotech) was added at different concentrations (as indicated) and PMN activation was analyzed by flow cytometry following 30 min of incubation.

Techniques: Activation Assay, Infection, Expressing

FIGURE 5. Blocking of C5a or C5aR decreases initial phagocytosis of C. albicans by PMN. Presence of the anti-C5a (A) or the anti-C5aR Ab (B) signifi- cantly reduced phagocytosis of C. albicans by blood PMN after 10 min of infection but not after 60 min. Non- and isotype control–treated C. albicans samples served as references. C. albicans association with blood PMN was determined by flow cytometry. Each dot represents the percentage of fungal cells phagocytosed by PMN relative to total C. albicans in blood (set to 100%) of independent experiments with blood from different donors. The mean 6 SD is given. *p , 0.05, ***p , 0.001. ns, nonsignificant.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a.

doi: 10.4049/jimmunol.1401845

Figure Lengend Snippet: FIGURE 5. Blocking of C5a or C5aR decreases initial phagocytosis of C. albicans by PMN. Presence of the anti-C5a (A) or the anti-C5aR Ab (B) signifi- cantly reduced phagocytosis of C. albicans by blood PMN after 10 min of infection but not after 60 min. Non- and isotype control–treated C. albicans samples served as references. C. albicans association with blood PMN was determined by flow cytometry. Each dot represents the percentage of fungal cells phagocytosed by PMN relative to total C. albicans in blood (set to 100%) of independent experiments with blood from different donors. The mean 6 SD is given. *p , 0.05, ***p , 0.001. ns, nonsignificant.

Article Snippet: In selected experiments, recombinant human C5a (Hycult Biotech) was added at different concentrations (as indicated) and PMN activation was analyzed by flow cytometry following 30 min of incubation.

Techniques: Blocking Assay, Infection, Control, Cytometry

FIGURE 6. C5a influences CD11b ex- pression on PMN in infected blood. CD11b expression on PMN in whole blood was analyzed 10 and 60 min after inoculation of C. albicans and compared with basal levels in mock-infected blood (gray filled histo- grams). Black open histograms indicate surface levels following C. albicans infec- tion and differentiate between PMN without fungal contact (dashed line) and PMN that interact with C. albicans (dotted line). C. albicans–infected samples were either nontreated [(a), top and bottom, respec- tively] or preincubated with IgG4 [(b), top and bottom, respectively] or anti-C5a [(c), top and bottom, respectively]. Data from one of at least three independent experiments with virtually identical results are shown.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a.

doi: 10.4049/jimmunol.1401845

Figure Lengend Snippet: FIGURE 6. C5a influences CD11b ex- pression on PMN in infected blood. CD11b expression on PMN in whole blood was analyzed 10 and 60 min after inoculation of C. albicans and compared with basal levels in mock-infected blood (gray filled histo- grams). Black open histograms indicate surface levels following C. albicans infec- tion and differentiate between PMN without fungal contact (dashed line) and PMN that interact with C. albicans (dotted line). C. albicans–infected samples were either nontreated [(a), top and bottom, respec- tively] or preincubated with IgG4 [(b), top and bottom, respectively] or anti-C5a [(c), top and bottom, respectively]. Data from one of at least three independent experiments with virtually identical results are shown.

Article Snippet: In selected experiments, recombinant human C5a (Hycult Biotech) was added at different concentrations (as indicated) and PMN activation was analyzed by flow cytometry following 30 min of incubation.

Techniques: Infection, Expressing

FIGURE 9. C5a induces PMN to phagocytose C. albicans in a mor- photype-independent manner. (A) C. albicans wild-type (;) and the nonfilamentous mutant cph1D/efg1D (d) resulted in equal C5a plasma levels during whole-blood infection. Dots show means 6 SD of five in- dependent experiments with whole blood from different donors. (B and C) Samples of human whole blood were infected with either FITC-labeled C. albicans wild-type and cph1D/efg1D (B) or killed GFP-expressing C. albicans wild-type yeast cells and filaments (C). Association with blood PMN after 60 min of confrontation was determined in the presence of IFX- 1 and compared with either IgG4-containig or nontreated C. albicans– infected blood (set to 100%) using flow cytometry. The bars show mean 6 SD of three independent experiments with blood from different donors. *p , 0.05.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a.

doi: 10.4049/jimmunol.1401845

Figure Lengend Snippet: FIGURE 9. C5a induces PMN to phagocytose C. albicans in a mor- photype-independent manner. (A) C. albicans wild-type (;) and the nonfilamentous mutant cph1D/efg1D (d) resulted in equal C5a plasma levels during whole-blood infection. Dots show means 6 SD of five in- dependent experiments with whole blood from different donors. (B and C) Samples of human whole blood were infected with either FITC-labeled C. albicans wild-type and cph1D/efg1D (B) or killed GFP-expressing C. albicans wild-type yeast cells and filaments (C). Association with blood PMN after 60 min of confrontation was determined in the presence of IFX- 1 and compared with either IgG4-containig or nontreated C. albicans– infected blood (set to 100%) using flow cytometry. The bars show mean 6 SD of three independent experiments with blood from different donors. *p , 0.05.

Article Snippet: In selected experiments, recombinant human C5a (Hycult Biotech) was added at different concentrations (as indicated) and PMN activation was analyzed by flow cytometry following 30 min of incubation.

Techniques: Mutagenesis, Clinical Proteomics, Infection, Labeling, Expressing, Cytometry

( A ) Shown are representative fields from 3 independent experiments. Complement proteins C3a and C5a increased the expression of ECM proteins in THP1 macrophages, BMDMs, and HK2 proximal tubule cells after 72 hours of treatment in serum-free medium. Scale bars: 50 μm. ( B – D ) The scatter plots show the mean staining intensity per THP-1 macrophage ( B ), BMDM ( C ), and HK2 proximal tubule cell ( D ), normalized to expression levels in their respective vehicle-treated groups. Each data point corresponds to quantified fluorescence intensity in a single field of view (FOV) from the microscope, and the larger dots represent the average of FOVs in biological replicates, each of which is color coded. RT-qPCR analysis of ECM protein coding genes were measured in BMDMs ( E ) and in HK2 proximal tubule cells ( F ). Gene expression was normalized to the expression of 18S ribosomal RNA in the same sample and then normalized to the expression level of vehicle-treated group ( n = 4). * P < 0.05, ** P < 0.01, and *** P < 0.001 by 2-tailed Student’s t test.

Journal: The Journal of Clinical Investigation

Article Title: Urine proteins reveal distinct coagulation and complement cascades underlying acute versus chronic lupus nephritis

doi: 10.1172/JCI186143

Figure Lengend Snippet: ( A ) Shown are representative fields from 3 independent experiments. Complement proteins C3a and C5a increased the expression of ECM proteins in THP1 macrophages, BMDMs, and HK2 proximal tubule cells after 72 hours of treatment in serum-free medium. Scale bars: 50 μm. ( B – D ) The scatter plots show the mean staining intensity per THP-1 macrophage ( B ), BMDM ( C ), and HK2 proximal tubule cell ( D ), normalized to expression levels in their respective vehicle-treated groups. Each data point corresponds to quantified fluorescence intensity in a single field of view (FOV) from the microscope, and the larger dots represent the average of FOVs in biological replicates, each of which is color coded. RT-qPCR analysis of ECM protein coding genes were measured in BMDMs ( E ) and in HK2 proximal tubule cells ( F ). Gene expression was normalized to the expression of 18S ribosomal RNA in the same sample and then normalized to the expression level of vehicle-treated group ( n = 4). * P < 0.05, ** P < 0.01, and *** P < 0.001 by 2-tailed Student’s t test.

Article Snippet: After 3 days of differentiation, the medium was replaced with serum-free medium for 24 hours, after which the cells were treated for 72 hours with either vehicle or 10 ng/mL C3a (R&D Systems 3677-C3-025) or 10 ng/mL of C5a (R&D Systems 2037-C5-025/CF).

Techniques: Expressing, Staining, Fluorescence, Microscopy, Quantitative RT-PCR, Gene Expression

Circulating immune complexes and Abs planted directly within glomerular and tubulo-interstitial regions of the kidneys may fix complement, resulting in complement activation. The alternative pathway may further amplify complement activation within the kidneys. The products of C3 and C5 convertases, including the anaphylatoxins C3a and C5a, engage cognate receptors on a wide spectrum of immune cells, leading to immune cell activation, release of cytokines and chemokines, and acute inflammation, leading to high AI, as depicted on the left. Long-standing, unresolved complement activation and eventual formation of MAC may additionally engage and activate more immune and renal-resident cells, leading to tissue damage and repair, ECM deposition, and renal fibrosis, leading to high CI, as depicted on the right.

Journal: The Journal of Clinical Investigation

Article Title: Urine proteins reveal distinct coagulation and complement cascades underlying acute versus chronic lupus nephritis

doi: 10.1172/JCI186143

Figure Lengend Snippet: Circulating immune complexes and Abs planted directly within glomerular and tubulo-interstitial regions of the kidneys may fix complement, resulting in complement activation. The alternative pathway may further amplify complement activation within the kidneys. The products of C3 and C5 convertases, including the anaphylatoxins C3a and C5a, engage cognate receptors on a wide spectrum of immune cells, leading to immune cell activation, release of cytokines and chemokines, and acute inflammation, leading to high AI, as depicted on the left. Long-standing, unresolved complement activation and eventual formation of MAC may additionally engage and activate more immune and renal-resident cells, leading to tissue damage and repair, ECM deposition, and renal fibrosis, leading to high CI, as depicted on the right.

Article Snippet: After 3 days of differentiation, the medium was replaced with serum-free medium for 24 hours, after which the cells were treated for 72 hours with either vehicle or 10 ng/mL C3a (R&D Systems 3677-C3-025) or 10 ng/mL of C5a (R&D Systems 2037-C5-025/CF).

Techniques: Activation Assay

Time- and dose-dependent cytotoxicity and apoptosis assays on Glomerular Endothelial Cells (GECs) and Podocytes. GECs. Time-dependent XTT citotoxity assay on GECs ( A ) and podocytes ( B ) incubated with a medium containing CK (20 ng/mL TNF-α, 2.5 ng/mL IL-6, and 50 ng/mL human recombinant C5a protein) or vehicle alone at different time-points (12, 18, 24, 36, 48 h) Significant differences in viability were observed on both GECs and podocytes at 18, 24, 36, and 48 h (* p < 0.05, CK vs. vehicle). At 12 h, only the GECs (A) had different viability between treated (CK) and control cells (vehicle, * p < 0.05, CK vs. vehicle). Cytotoxicity tests by XTT ( C ) and apoptosis by TUNEL assay ( D ), evaluating the protective dose of EPC-derived EVs on GECs (black columns) and podocytes (white columns) after 24 h. Incubation with CK alone was effective in inducing cytotoxic (C) and apoptotic damage (D) in both cell types (* p < 0.05, CK vs. vehicle). Adding 1 or 10 μg/mL EPC-derived EVs to cells incubated with CK did not significantly reduce cell damage (* p < 0.05, CK + 1 μg/mL EV and CK + 10 μg/mL EV vs. vehicle), except with GEC incubated with 10 μg/mL EV in TUNEL assay (§ CK + 10 μg/mL EV vs. CK). In contrast, the adding of 25 or 50 μg/mL EPC-derived EVs to cells incubated with CK significantly reduced cell damage at the level of GECs and podocytes (§ p < 0.05, CK + 25 μg/mL EV and CK + 50 μg/mL EV vs. CK). XTT assays are reported as average optical density (O.D.) intensity ± 1SD. For TUNEL assays, data are expressed as the average number of green fluorescent apoptotic cells ± 1 SD. We performed three experiments for each test and the statistical analysis by ANOVA with Newmann–Keuls multiple comparison test.

Journal: Cells

Article Title: Extracellular Vesicles Derived from Endothelial Progenitor Cells Protect Human Glomerular Endothelial Cells and Podocytes from Complement- and Cytokine-Mediated Injury

doi: 10.3390/cells10071675

Figure Lengend Snippet: Time- and dose-dependent cytotoxicity and apoptosis assays on Glomerular Endothelial Cells (GECs) and Podocytes. GECs. Time-dependent XTT citotoxity assay on GECs ( A ) and podocytes ( B ) incubated with a medium containing CK (20 ng/mL TNF-α, 2.5 ng/mL IL-6, and 50 ng/mL human recombinant C5a protein) or vehicle alone at different time-points (12, 18, 24, 36, 48 h) Significant differences in viability were observed on both GECs and podocytes at 18, 24, 36, and 48 h (* p < 0.05, CK vs. vehicle). At 12 h, only the GECs (A) had different viability between treated (CK) and control cells (vehicle, * p < 0.05, CK vs. vehicle). Cytotoxicity tests by XTT ( C ) and apoptosis by TUNEL assay ( D ), evaluating the protective dose of EPC-derived EVs on GECs (black columns) and podocytes (white columns) after 24 h. Incubation with CK alone was effective in inducing cytotoxic (C) and apoptotic damage (D) in both cell types (* p < 0.05, CK vs. vehicle). Adding 1 or 10 μg/mL EPC-derived EVs to cells incubated with CK did not significantly reduce cell damage (* p < 0.05, CK + 1 μg/mL EV and CK + 10 μg/mL EV vs. vehicle), except with GEC incubated with 10 μg/mL EV in TUNEL assay (§ CK + 10 μg/mL EV vs. CK). In contrast, the adding of 25 or 50 μg/mL EPC-derived EVs to cells incubated with CK significantly reduced cell damage at the level of GECs and podocytes (§ p < 0.05, CK + 25 μg/mL EV and CK + 50 μg/mL EV vs. CK). XTT assays are reported as average optical density (O.D.) intensity ± 1SD. For TUNEL assays, data are expressed as the average number of green fluorescent apoptotic cells ± 1 SD. We performed three experiments for each test and the statistical analysis by ANOVA with Newmann–Keuls multiple comparison test.

Article Snippet: In selected experiments, we incubated cells in an appropriate medium containing 20 ng/mL tumor necrosis factor (TNF)-α (Sigma Aldrich), 2.5 ng/mL IL-6, and 50 ng/mL human recombinant C5a protein (R&D Systems, Minneapolis, MN, USA) in the presence or absence of different concentrations of EPC-derived EVs assessed by Nanosight analysis.

Techniques: Incubation, Recombinant, Control, TUNEL Assay, Derivative Assay, Comparison

EPC-derived EVs protected GECs from complement- and cytokine-induced damage ( A , B ). Graphs showing GEC cytotoxicity by XTT assay ( A ) and apoptosis by TUNEL assay ( B ). For XTT assays, data are expressed as average OD intensity ± 1 SD, whereas we expressed TUNEL assays data as the average number of green fluorescent apoptotic cells ± 1 SD. We performed three experiments with similar results for all the assays and the statistical analysis by ANOVA with Newmann–Keuls multiple comparison test and Student’s t -test. ( C , D ) FACS analysis ( C ) and representative micrographs ( D ) of ROS expression of GEC (green staining) by confocal microscopy studies (magnification ×400, scale bar 50 μm). Nuclei were counterstained in blue by 2.5 μg/mL Hoechst. We performed three experiments with similar results for all the assays, and we performed the statistical analysis by ANOVA with Newmann–Keuls multiple comparison test and the Kolmogorov–Smirnov test. Incubation with cytokines 20 ng/mL TNF -α, 2.5 ng/mL IL-6, plus 50 ng/mL human recombinant C5a protein CKs significantly increased GEC vitality ( A ), inhibited resistance to apoptosis ( B ), and increased oxidative stress (C) in comparison to treatment with vehicle alone (vehicle, * p < 0.05 CK vs. vehicle). EV stimulation significantly inhibited these effects (§ p < 0.05 CK + EV vs. CK), but not EV were pre-treated with 1 U/mL RNase (# p < 0.05 CK + EV RNase vs. CK + EV).

Journal: Cells

Article Title: Extracellular Vesicles Derived from Endothelial Progenitor Cells Protect Human Glomerular Endothelial Cells and Podocytes from Complement- and Cytokine-Mediated Injury

doi: 10.3390/cells10071675

Figure Lengend Snippet: EPC-derived EVs protected GECs from complement- and cytokine-induced damage ( A , B ). Graphs showing GEC cytotoxicity by XTT assay ( A ) and apoptosis by TUNEL assay ( B ). For XTT assays, data are expressed as average OD intensity ± 1 SD, whereas we expressed TUNEL assays data as the average number of green fluorescent apoptotic cells ± 1 SD. We performed three experiments with similar results for all the assays and the statistical analysis by ANOVA with Newmann–Keuls multiple comparison test and Student’s t -test. ( C , D ) FACS analysis ( C ) and representative micrographs ( D ) of ROS expression of GEC (green staining) by confocal microscopy studies (magnification ×400, scale bar 50 μm). Nuclei were counterstained in blue by 2.5 μg/mL Hoechst. We performed three experiments with similar results for all the assays, and we performed the statistical analysis by ANOVA with Newmann–Keuls multiple comparison test and the Kolmogorov–Smirnov test. Incubation with cytokines 20 ng/mL TNF -α, 2.5 ng/mL IL-6, plus 50 ng/mL human recombinant C5a protein CKs significantly increased GEC vitality ( A ), inhibited resistance to apoptosis ( B ), and increased oxidative stress (C) in comparison to treatment with vehicle alone (vehicle, * p < 0.05 CK vs. vehicle). EV stimulation significantly inhibited these effects (§ p < 0.05 CK + EV vs. CK), but not EV were pre-treated with 1 U/mL RNase (# p < 0.05 CK + EV RNase vs. CK + EV).

Article Snippet: In selected experiments, we incubated cells in an appropriate medium containing 20 ng/mL tumor necrosis factor (TNF)-α (Sigma Aldrich), 2.5 ng/mL IL-6, and 50 ng/mL human recombinant C5a protein (R&D Systems, Minneapolis, MN, USA) in the presence or absence of different concentrations of EPC-derived EVs assessed by Nanosight analysis.

Techniques: Derivative Assay, XTT Assay, TUNEL Assay, Comparison, Expressing, Staining, Confocal Microscopy, Incubation, Recombinant

Selected potential paclitaxel targets and their predicted affinity.

Journal: Cell Death & Disease

Article Title: Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions

doi: 10.1038/s41419-022-04964-w

Figure Lengend Snippet: Selected potential paclitaxel targets and their predicted affinity.

Article Snippet: The reagents that have been used are: recombinant human C5a anaphylotoxin chemotactic receptor 2 (C5AR2) (CUSABIO TECHNOLOGY, Houston, TX, US), recombinant protein of human complement component 5a receptor 1 (C5AR1) (Origene, Rockville, MD, US), anti-6X His tag antibody (Abcam, Cambridge, UK), Anti-Myc/c-Myc Antibody (9E10) (Santa Cruz Biotechnology, Dallas, Texas, US) and CD88 (clone S5/1) antibody (344302, Biolegend, San Diego, California, US), complement C5a des-Arg, Human (Merck, Burlington, Massachusetts, USA).

Techniques:

( A ) Binding of paclitaxel on immobilized C5aR1, C5aR2, C5a, and C5a des-Arg. ( B ) Dose-dependent binding of paclitaxel on immobilized C5aR1. ( C , D ) Co-injection of paclitaxel and C5aR1 on immobilized C5a and relative IC50. ( E , F ) Co-injection of paclitaxel and C5aR1 on immobilized C5a des-Arg and relative IC50. G , H Co-injection of paclitaxel and C5aR1 on immobilized monoclonal antibody anti-C5aR1 and relative IC50.

Journal: Cell Death & Disease

Article Title: Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions

doi: 10.1038/s41419-022-04964-w

Figure Lengend Snippet: ( A ) Binding of paclitaxel on immobilized C5aR1, C5aR2, C5a, and C5a des-Arg. ( B ) Dose-dependent binding of paclitaxel on immobilized C5aR1. ( C , D ) Co-injection of paclitaxel and C5aR1 on immobilized C5a and relative IC50. ( E , F ) Co-injection of paclitaxel and C5aR1 on immobilized C5a des-Arg and relative IC50. G , H Co-injection of paclitaxel and C5aR1 on immobilized monoclonal antibody anti-C5aR1 and relative IC50.

Article Snippet: The reagents that have been used are: recombinant human C5a anaphylotoxin chemotactic receptor 2 (C5AR2) (CUSABIO TECHNOLOGY, Houston, TX, US), recombinant protein of human complement component 5a receptor 1 (C5AR1) (Origene, Rockville, MD, US), anti-6X His tag antibody (Abcam, Cambridge, UK), Anti-Myc/c-Myc Antibody (9E10) (Santa Cruz Biotechnology, Dallas, Texas, US) and CD88 (clone S5/1) antibody (344302, Biolegend, San Diego, California, US), complement C5a des-Arg, Human (Merck, Burlington, Massachusetts, USA).

Techniques: Binding Assay, Injection

Representative trace of electrophysiological recordings in DRG cells maintained under basal conditions ( A ), and in cells challenged with paclitaxel (10 nM) (PAC) ( B ), paclitaxel+DF3966A (1 µM) ( C ), C5a (100 nM) ( D ) or C5a + DF3966A ( E ). Quantitative evaluation of action potential firing rate in DRG exposed to paclitaxel alone or in combination with DF3966A ( F ), and C5a alone or in combination with DF3966A ( G ). DRG-derived neurons were cultured for 7 days. Cells were treated for 1 min 30 s (short) or 5 min (long). ** P < 0.005 and * P < 0.05 vs respective basal condition; + P < 0.05 vs paclitaxel or C5a. Data are mean ± SEM of n = 3 different experiments.

Journal: Cell Death & Disease

Article Title: Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions

doi: 10.1038/s41419-022-04964-w

Figure Lengend Snippet: Representative trace of electrophysiological recordings in DRG cells maintained under basal conditions ( A ), and in cells challenged with paclitaxel (10 nM) (PAC) ( B ), paclitaxel+DF3966A (1 µM) ( C ), C5a (100 nM) ( D ) or C5a + DF3966A ( E ). Quantitative evaluation of action potential firing rate in DRG exposed to paclitaxel alone or in combination with DF3966A ( F ), and C5a alone or in combination with DF3966A ( G ). DRG-derived neurons were cultured for 7 days. Cells were treated for 1 min 30 s (short) or 5 min (long). ** P < 0.005 and * P < 0.05 vs respective basal condition; + P < 0.05 vs paclitaxel or C5a. Data are mean ± SEM of n = 3 different experiments.

Article Snippet: The reagents that have been used are: recombinant human C5a anaphylotoxin chemotactic receptor 2 (C5AR2) (CUSABIO TECHNOLOGY, Houston, TX, US), recombinant protein of human complement component 5a receptor 1 (C5AR1) (Origene, Rockville, MD, US), anti-6X His tag antibody (Abcam, Cambridge, UK), Anti-Myc/c-Myc Antibody (9E10) (Santa Cruz Biotechnology, Dallas, Texas, US) and CD88 (clone S5/1) antibody (344302, Biolegend, San Diego, California, US), complement C5a des-Arg, Human (Merck, Burlington, Massachusetts, USA).

Techniques: Derivative Assay, Cell Culture

Proteome profiles of cytokines released from RAW 264.7 ( A , B ) and human ( C , D ) macrophages challenged with C5a ( A , C ) or paclitaxel ( B , D ) alone or in combination with a C5AR1 antibody (anti C5AR), Avacopan or DF3966A. RAW 264.7 and human macrophages cells were treated with C5a (10 nM), or paclitaxel (PAC) (10 nM), or DF3966A (1 μM) or Avacopan (1 μM) and C5aR1 antibody (1 μM) for 24 h. Data are mean ± SEM of n = 3 different experiments.

Journal: Cell Death & Disease

Article Title: Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions

doi: 10.1038/s41419-022-04964-w

Figure Lengend Snippet: Proteome profiles of cytokines released from RAW 264.7 ( A , B ) and human ( C , D ) macrophages challenged with C5a ( A , C ) or paclitaxel ( B , D ) alone or in combination with a C5AR1 antibody (anti C5AR), Avacopan or DF3966A. RAW 264.7 and human macrophages cells were treated with C5a (10 nM), or paclitaxel (PAC) (10 nM), or DF3966A (1 μM) or Avacopan (1 μM) and C5aR1 antibody (1 μM) for 24 h. Data are mean ± SEM of n = 3 different experiments.

Article Snippet: The reagents that have been used are: recombinant human C5a anaphylotoxin chemotactic receptor 2 (C5AR2) (CUSABIO TECHNOLOGY, Houston, TX, US), recombinant protein of human complement component 5a receptor 1 (C5AR1) (Origene, Rockville, MD, US), anti-6X His tag antibody (Abcam, Cambridge, UK), Anti-Myc/c-Myc Antibody (9E10) (Santa Cruz Biotechnology, Dallas, Texas, US) and CD88 (clone S5/1) antibody (344302, Biolegend, San Diego, California, US), complement C5a des-Arg, Human (Merck, Burlington, Massachusetts, USA).

Techniques:

(a,b) Degradation of recombinant C5a by cultures supernatant containing the C5a-peptidase enzyme (ScpA). GAS was grown in CDM without or with Asn or/and LL-37. Supernatants of the indicated strains were incubated with recombinant human C5a, resolved on Tris-tricine gels, and visualized by Coomassie blue staining. M represents a marker, and an empty arrow is the cleaved C5a. The data are representative of 2 independent experiments. (c,d) Quantitation of IL-8 degradation by ScpC present in the supernatants of the indicated strains by ELISA. n=2 . The data shown represent the means ± S.D. (e) Asn does not affect in-vitro CovR phosphorylation . Purified CovR was incubated in the absence (−) and presence (+) of acetyl phosphate (Ac-P) as a phosphate donor and the indicated concentrations of Asn (µg ml -1 ). The protein samples were resolved on Phos-tag SDS-PAGE gel and visualized.

Journal: bioRxiv

Article Title: Asparagine couples group A Streptococcal metabolism to virulence

doi: 10.1101/2024.07.08.602371

Figure Lengend Snippet: (a,b) Degradation of recombinant C5a by cultures supernatant containing the C5a-peptidase enzyme (ScpA). GAS was grown in CDM without or with Asn or/and LL-37. Supernatants of the indicated strains were incubated with recombinant human C5a, resolved on Tris-tricine gels, and visualized by Coomassie blue staining. M represents a marker, and an empty arrow is the cleaved C5a. The data are representative of 2 independent experiments. (c,d) Quantitation of IL-8 degradation by ScpC present in the supernatants of the indicated strains by ELISA. n=2 . The data shown represent the means ± S.D. (e) Asn does not affect in-vitro CovR phosphorylation . Purified CovR was incubated in the absence (−) and presence (+) of acetyl phosphate (Ac-P) as a phosphate donor and the indicated concentrations of Asn (µg ml -1 ). The protein samples were resolved on Phos-tag SDS-PAGE gel and visualized.

Article Snippet: The cell-free supernatants were incubated with 1 mg/ml of purified recombinant human complement component C5a (R&D Systems, USA) at 37°C for 2 h. The samples were heated at 100°C for 5 min with 4x Tricine loading buffer (0.4 M Tris HCl pH 6.8, 80% glycerol, 4% SDS, and 0.08% Coomassie blue) to stop the reaction.

Techniques: Recombinant, Incubation, Staining, Marker, Quantitation Assay, Enzyme-linked Immunosorbent Assay, In Vitro, Phospho-proteomics, Purification, SDS Page

RNA interference suppresses local complement activation. BALF collected from Figure 1 were analyzed for C3a (A) and C5a (B) levels in the lung by ELISA. Values: Means ± SEM. (n=5-7 per group). One-way ANOVA, Newman-Keuls (A, B). Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. Results are representative of three independent experiments.

Journal: Cellular & molecular medicine: open access

Article Title: Potential Mechanisms Underlying TGF-β-mediated Complement Activation in Lung Fibrosis

doi:

Figure Lengend Snippet: RNA interference suppresses local complement activation. BALF collected from Figure 1 were analyzed for C3a (A) and C5a (B) levels in the lung by ELISA. Values: Means ± SEM. (n=5-7 per group). One-way ANOVA, Newman-Keuls (A, B). Compared to bleomycin: ***: p<0.001; **: p<0.01; *: p<0.05. Results are representative of three independent experiments.

Article Snippet: These studies used recombinant human C3a and C5a (100 nM; Complement Technology, Inc., Tyler, TX), platelet-derived TGF-β1 (2 ng/ml; Roche Diagnostics, Germany).

Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay

miRNA regulation in response to TGF-β, C3a and  C5a  for 24 h in normal primary human SAECs.

Journal: Cellular & molecular medicine: open access

Article Title: Potential Mechanisms Underlying TGF-β-mediated Complement Activation in Lung Fibrosis

doi:

Figure Lengend Snippet: miRNA regulation in response to TGF-β, C3a and C5a for 24 h in normal primary human SAECs.

Article Snippet: These studies used recombinant human C3a and C5a (100 nM; Complement Technology, Inc., Tyler, TX), platelet-derived TGF-β1 (2 ng/ml; Roche Diagnostics, Germany).

Techniques:

PMN migrate using CD18-independent mechanisms across T84 monolayers growing on the bottom of Transwell filters. Migration to fMLP (10−7m), C5a (10−8m), IL-8 (10−8m) and LTB4 (10−6m) of PMN without added mAb (▪) or anti-CD18 mAb pretreated PMN (). The data is from between six and 11 experiments and the mean of means ± standard error of the mean are shown. Values with control mAb treatment were similar to migration in absence of antibody for each chemoattractant (not shown).

Journal:

Article Title: Neutrophils migrate across intestinal epithelium using ? 2 integrin (CD11b/CD18)-independent mechanisms

doi: 10.1111/j.1365-2249.2004.02429.x

Figure Lengend Snippet: PMN migrate using CD18-independent mechanisms across T84 monolayers growing on the bottom of Transwell filters. Migration to fMLP (10−7m), C5a (10−8m), IL-8 (10−8m) and LTB4 (10−6m) of PMN without added mAb (▪) or anti-CD18 mAb pretreated PMN (). The data is from between six and 11 experiments and the mean of means ± standard error of the mean are shown. Values with control mAb treatment were similar to migration in absence of antibody for each chemoattractant (not shown).

Article Snippet: Recombinant human C5a was a gift from CIBA-Geigy (Summit, NJ, USA), recombinant human IL-8 (72 amino acids) was purchased from Peprotech Inc. (Rocky Hill, NJ, USA), fMLP from Sigma Chemical Company (Oakville, Canada) and LTB 4 from Cayman Chemical Company (Cedarlane, Hornby, Canada).

Techniques: Migration, Control

Time course of PMN migration to C5a, in the absence of mAb (▪) or with anti-CD18 mAb () across T84 monolayers growing on the bottom of Transwell filters. PMN were incubated with the mAb prior to adding to the Transwell and the migrated fraction was harvested at the time indicated and the 51Cr content determined. Shown is the mean ± standard deviation of three Transwells of a representative experiment.

Journal:

Article Title: Neutrophils migrate across intestinal epithelium using ? 2 integrin (CD11b/CD18)-independent mechanisms

doi: 10.1111/j.1365-2249.2004.02429.x

Figure Lengend Snippet: Time course of PMN migration to C5a, in the absence of mAb (▪) or with anti-CD18 mAb () across T84 monolayers growing on the bottom of Transwell filters. PMN were incubated with the mAb prior to adding to the Transwell and the migrated fraction was harvested at the time indicated and the 51Cr content determined. Shown is the mean ± standard deviation of three Transwells of a representative experiment.

Article Snippet: Recombinant human C5a was a gift from CIBA-Geigy (Summit, NJ, USA), recombinant human IL-8 (72 amino acids) was purchased from Peprotech Inc. (Rocky Hill, NJ, USA), fMLP from Sigma Chemical Company (Oakville, Canada) and LTB 4 from Cayman Chemical Company (Cedarlane, Hornby, Canada).

Techniques: Migration, Incubation, Standard Deviation

PMN CD18-dependent migration across T84 monolayers is CD11b-dependent. PMN were incubated with mAb to (a) CD18, CD11b or (b) CD11a prior to adding to the well, then after 2 h incubation the migrated fraction of cells was recovered. All the treatment groups in (b) were migrated in response to C5a.

Journal:

Article Title: Neutrophils migrate across intestinal epithelium using ? 2 integrin (CD11b/CD18)-independent mechanisms

doi: 10.1111/j.1365-2249.2004.02429.x

Figure Lengend Snippet: PMN CD18-dependent migration across T84 monolayers is CD11b-dependent. PMN were incubated with mAb to (a) CD18, CD11b or (b) CD11a prior to adding to the well, then after 2 h incubation the migrated fraction of cells was recovered. All the treatment groups in (b) were migrated in response to C5a.

Article Snippet: Recombinant human C5a was a gift from CIBA-Geigy (Summit, NJ, USA), recombinant human IL-8 (72 amino acids) was purchased from Peprotech Inc. (Rocky Hill, NJ, USA), fMLP from Sigma Chemical Company (Oakville, Canada) and LTB 4 from Cayman Chemical Company (Cedarlane, Hornby, Canada).

Techniques: Migration, Incubation

Migration of PMN across T84 monolayers in the apical-to-basolateral direction is CD18-dependent. (a) Comparison of migration in the basolateral-to-apical (T84 grown on the filter bottom) versus apical-to-basolateral (T84 grown on the filter top) directions to multiple C5a concentrations. ▪ migration across T84 monolayers in absence of antibody; () migration in presence of mAb to anti-CD18. (b) Fraction of PMN remaining adherent to T84 monolayers following a two hour migration period in response to C5a; the data is collected from the same experiments as (a). ▪ adherent PMN in absence of antibody; () adherent PMN in the presence of anti-CD18 mAb. Shown are the means ± standard deviation of three Transwells from one experiment. The experiment was repeated twice more using only the 10−8 C5a concentration, with similar results.

Journal:

Article Title: Neutrophils migrate across intestinal epithelium using ? 2 integrin (CD11b/CD18)-independent mechanisms

doi: 10.1111/j.1365-2249.2004.02429.x

Figure Lengend Snippet: Migration of PMN across T84 monolayers in the apical-to-basolateral direction is CD18-dependent. (a) Comparison of migration in the basolateral-to-apical (T84 grown on the filter bottom) versus apical-to-basolateral (T84 grown on the filter top) directions to multiple C5a concentrations. ▪ migration across T84 monolayers in absence of antibody; () migration in presence of mAb to anti-CD18. (b) Fraction of PMN remaining adherent to T84 monolayers following a two hour migration period in response to C5a; the data is collected from the same experiments as (a). ▪ adherent PMN in absence of antibody; () adherent PMN in the presence of anti-CD18 mAb. Shown are the means ± standard deviation of three Transwells from one experiment. The experiment was repeated twice more using only the 10−8 C5a concentration, with similar results.

Article Snippet: Recombinant human C5a was a gift from CIBA-Geigy (Summit, NJ, USA), recombinant human IL-8 (72 amino acids) was purchased from Peprotech Inc. (Rocky Hill, NJ, USA), fMLP from Sigma Chemical Company (Oakville, Canada) and LTB 4 from Cayman Chemical Company (Cedarlane, Hornby, Canada).

Techniques: Migration, Comparison, Standard Deviation, Concentration Assay

CD18-independent PMN migration induced by C5a or IL-8 plus LTB4 persists in the presence of fMLP. (a) The effect 10−8 M C5a and 10−7 M fMLP combined in the bottom chamber on PMN migration. Pooled data of four experiments ± standard error of the mean are shown. The difference between the three nonmAb treated groups (▪) in which a chemoattractant was used were not significant; however, each of the anti-CD18 treated groups () were significantly (P < 0·001) different from each other. (b) CD18-independent migration persists when IL-8 and LTB4 are combined with fMLP in the bottom chamber of the Transwell. No mAb (▪); PMN pretreated with anti-CD18 mAb (). nd = not done. Shown is the mean ± standard deviation of three wells from a single donor; one of two experiments.

Journal:

Article Title: Neutrophils migrate across intestinal epithelium using ? 2 integrin (CD11b/CD18)-independent mechanisms

doi: 10.1111/j.1365-2249.2004.02429.x

Figure Lengend Snippet: CD18-independent PMN migration induced by C5a or IL-8 plus LTB4 persists in the presence of fMLP. (a) The effect 10−8 M C5a and 10−7 M fMLP combined in the bottom chamber on PMN migration. Pooled data of four experiments ± standard error of the mean are shown. The difference between the three nonmAb treated groups (▪) in which a chemoattractant was used were not significant; however, each of the anti-CD18 treated groups () were significantly (P < 0·001) different from each other. (b) CD18-independent migration persists when IL-8 and LTB4 are combined with fMLP in the bottom chamber of the Transwell. No mAb (▪); PMN pretreated with anti-CD18 mAb (). nd = not done. Shown is the mean ± standard deviation of three wells from a single donor; one of two experiments.

Article Snippet: Recombinant human C5a was a gift from CIBA-Geigy (Summit, NJ, USA), recombinant human IL-8 (72 amino acids) was purchased from Peprotech Inc. (Rocky Hill, NJ, USA), fMLP from Sigma Chemical Company (Oakville, Canada) and LTB 4 from Cayman Chemical Company (Cedarlane, Hornby, Canada).

Techniques: Migration, Standard Deviation

NF-κB activation 1 hour after in vitro or in vivo stimulation with IgG immune complexes in the absence or presence of C5a or MAC, as detected by the electrophoretic mobility shift assay (EMSA). Nuclear extracts of alveolar macrophages or whole lung nuclei were used. The position of NF-κB (p50, p65) is indicated by the arrows.

Journal:

Article Title: Synergistic Enhancement of Chemokine Generation and Lung Injury by C5a or the Membrane Attack Complex of Complement

doi:

Figure Lengend Snippet: NF-κB activation 1 hour after in vitro or in vivo stimulation with IgG immune complexes in the absence or presence of C5a or MAC, as detected by the electrophoretic mobility shift assay (EMSA). Nuclear extracts of alveolar macrophages or whole lung nuclei were used. The position of NF-κB (p50, p65) is indicated by the arrows.

Article Snippet: Human recombinant C5a was purchased from Fluka Chemical Corp. (Ronkonkoma, NY).

Techniques: Activation Assay, In Vitro, In Vivo, Electrophoretic Mobility Shift Assay

Dose-responses for chemokine production in vitro by rat alveolar macrophages after stimulation with a constant dose (10 μg/ml) of IgG immune complexes (IC) together with increasing doses of C5a (25–150 ng/ml), frame A, or MAC (based on 2.5–10 μg C5/ml), frame B. MAC was assembled with a twofold excess of complement components C6-C9 to avoid cytolytic effects. Background chemokine production after stimulation with IgG alone (10 μg/ml) in the absence of complement components is shown with an asterisk.

Journal:

Article Title: Synergistic Enhancement of Chemokine Generation and Lung Injury by C5a or the Membrane Attack Complex of Complement

doi:

Figure Lengend Snippet: Dose-responses for chemokine production in vitro by rat alveolar macrophages after stimulation with a constant dose (10 μg/ml) of IgG immune complexes (IC) together with increasing doses of C5a (25–150 ng/ml), frame A, or MAC (based on 2.5–10 μg C5/ml), frame B. MAC was assembled with a twofold excess of complement components C6-C9 to avoid cytolytic effects. Background chemokine production after stimulation with IgG alone (10 μg/ml) in the absence of complement components is shown with an asterisk.

Article Snippet: Human recombinant C5a was purchased from Fluka Chemical Corp. (Ronkonkoma, NY).

Techniques: In Vitro

Chemokine generation in vitro after stimulation of rat alveolar macrophages (1 × 106/well) with 10 μg/ml IgG immune complexes (IC) for 4 hours. C5a was used at a concentration of 50 ng/ml. MAC was assembled on cell surfaces of alveolar macrophages in sublytic concentrations based on 10 μg C5/ml, with a twofold molar excess of components C6 to C9, in specified groups without C7 (MAC – C7). MAC was formed in the absence of C7. In this and in all succeeding relevant figures, where the y-axes are labeled “% of positive control,” values obtained with each treatment are shown as a percentage of values obtained when cells were treated with IgG immune complexes (IC, positive control). In addition, values obtained with no treatment (none) were subtracted from each data point before making comparisons between the relevant groups. The absolute values (ng/ml) for MIP-2, CINC, MCP-1, and MIP-1α obtained when macrophages were treated with IgG immune complexes (IC) were: 49.5 ± 2.72, 1158.0 ± 53.3, 22.6 ± 1.52, and 78.2 ± 2.86, respectively.

Journal:

Article Title: Synergistic Enhancement of Chemokine Generation and Lung Injury by C5a or the Membrane Attack Complex of Complement

doi:

Figure Lengend Snippet: Chemokine generation in vitro after stimulation of rat alveolar macrophages (1 × 106/well) with 10 μg/ml IgG immune complexes (IC) for 4 hours. C5a was used at a concentration of 50 ng/ml. MAC was assembled on cell surfaces of alveolar macrophages in sublytic concentrations based on 10 μg C5/ml, with a twofold molar excess of components C6 to C9, in specified groups without C7 (MAC – C7). MAC was formed in the absence of C7. In this and in all succeeding relevant figures, where the y-axes are labeled “% of positive control,” values obtained with each treatment are shown as a percentage of values obtained when cells were treated with IgG immune complexes (IC, positive control). In addition, values obtained with no treatment (none) were subtracted from each data point before making comparisons between the relevant groups. The absolute values (ng/ml) for MIP-2, CINC, MCP-1, and MIP-1α obtained when macrophages were treated with IgG immune complexes (IC) were: 49.5 ± 2.72, 1158.0 ± 53.3, 22.6 ± 1.52, and 78.2 ± 2.86, respectively.

Article Snippet: Human recombinant C5a was purchased from Fluka Chemical Corp. (Ronkonkoma, NY).

Techniques: In Vitro, Concentration Assay, Labeling, Positive Control

Lung vascular permeability in presence of a dose range (1.0–8.0 μg) of exogenously administered C5a during IgG immune complex (IC) deposition in lungs. Trace amounts of 125I-BSA were injected intravenously and albumin leak into lung (permeability index) was determined after 4 hours.

Journal:

Article Title: Synergistic Enhancement of Chemokine Generation and Lung Injury by C5a or the Membrane Attack Complex of Complement

doi:

Figure Lengend Snippet: Lung vascular permeability in presence of a dose range (1.0–8.0 μg) of exogenously administered C5a during IgG immune complex (IC) deposition in lungs. Trace amounts of 125I-BSA were injected intravenously and albumin leak into lung (permeability index) was determined after 4 hours.

Article Snippet: Human recombinant C5a was purchased from Fluka Chemical Corp. (Ronkonkoma, NY).

Techniques: Permeability, Injection

Intrinsic neutrophil chemotactic activity of human C5a and MAC. Fluorescein-labeled human neutrophils were exposed to the chemotactic activity of increasing concentrations of C5a (0.2–50 ng/ml) or preformed MAC (0.04–10 μg/ml). The amount of neutrophils that migrated after 30 minutes through a filter containing pores of 3 μm was assessed by measuring fluorescence in a cytofluorometer. The results are typical of data collected in two separate and independent experiments. Each data point was done in quadruplicate. SE values are not displayed because of the very small variances (<10% of x).

Journal:

Article Title: Synergistic Enhancement of Chemokine Generation and Lung Injury by C5a or the Membrane Attack Complex of Complement

doi:

Figure Lengend Snippet: Intrinsic neutrophil chemotactic activity of human C5a and MAC. Fluorescein-labeled human neutrophils were exposed to the chemotactic activity of increasing concentrations of C5a (0.2–50 ng/ml) or preformed MAC (0.04–10 μg/ml). The amount of neutrophils that migrated after 30 minutes through a filter containing pores of 3 μm was assessed by measuring fluorescence in a cytofluorometer. The results are typical of data collected in two separate and independent experiments. Each data point was done in quadruplicate. SE values are not displayed because of the very small variances (<10% of x).

Article Snippet: Human recombinant C5a was purchased from Fluka Chemical Corp. (Ronkonkoma, NY).

Techniques: Activity Assay, Labeling, Fluorescence

Enhanced permeability changes and accumulation of neutrophils (PMN) in BAL fluids after intrapulmonary deposition of IgG immune complexes (IC) using 1.25 mg anti-BSA in the absence or presence of C5a (2.0 μg) or MAC (based on 15 μg oxidized C5 with a twofold excess of complement components C6-C9). Cell content is shown as PMN/ml with a total volume of 3.0 ml. For each condition, n = 4.

Journal:

Article Title: Synergistic Enhancement of Chemokine Generation and Lung Injury by C5a or the Membrane Attack Complex of Complement

doi:

Figure Lengend Snippet: Enhanced permeability changes and accumulation of neutrophils (PMN) in BAL fluids after intrapulmonary deposition of IgG immune complexes (IC) using 1.25 mg anti-BSA in the absence or presence of C5a (2.0 μg) or MAC (based on 15 μg oxidized C5 with a twofold excess of complement components C6-C9). Cell content is shown as PMN/ml with a total volume of 3.0 ml. For each condition, n = 4.

Article Snippet: Human recombinant C5a was purchased from Fluka Chemical Corp. (Ronkonkoma, NY).

Techniques: Permeability

Chemokine levels in bronchoalveolar lavage (BAL) fluids 4 hours after deposition of IgG immune complexes (IC) in lung. The administered amount of C5a was 2.0 μg (as determined by the data in Figure 6 ▶ ). The assembly of MAC was achieved by intratracheal instillation of 15 μg C5b-like product (oxidized C5) together with C6 and C7 (omitted in some animals), each at 30 μg, followed by a second instillation after 10 minutes of C8 and C9, each at 30 μg. In the IgG immune complex-treated groups (IC) the BAL values (ng/ml) for these four chemokines were 51.3 ± 3.91, 2210.0 ± 67.1, 13.0 ± 1.10, and 63.0 ± 2.97, respectively. For each column, n = 4.

Journal:

Article Title: Synergistic Enhancement of Chemokine Generation and Lung Injury by C5a or the Membrane Attack Complex of Complement

doi:

Figure Lengend Snippet: Chemokine levels in bronchoalveolar lavage (BAL) fluids 4 hours after deposition of IgG immune complexes (IC) in lung. The administered amount of C5a was 2.0 μg (as determined by the data in Figure 6 ▶ ). The assembly of MAC was achieved by intratracheal instillation of 15 μg C5b-like product (oxidized C5) together with C6 and C7 (omitted in some animals), each at 30 μg, followed by a second instillation after 10 minutes of C8 and C9, each at 30 μg. In the IgG immune complex-treated groups (IC) the BAL values (ng/ml) for these four chemokines were 51.3 ± 3.91, 2210.0 ± 67.1, 13.0 ± 1.10, and 63.0 ± 2.97, respectively. For each column, n = 4.

Article Snippet: Human recombinant C5a was purchased from Fluka Chemical Corp. (Ronkonkoma, NY).

Techniques: